Utilizing the Yokohama System of the International Academy of Cytology to Report Breast Fine Needle Aspiration Cytology

Background-According to the most recent GLOBOCAN figures, breast cancer has become the most frequent cancer globally and is ranked sixth in terms of cancer death.The most reliable, safest, least intrusive, and economical method for evaluating palpable and nonpalpable breast lesions is breast fine-needle aspiration (FNA).It is best interpreted in conjunction with the other "triple test" elements in a multidisciplinary setting.Methods-For two years, the hospital's pathology data were checked for cases with breast FNAB.Additionally gathered and documented was the related clinicopathologic data, which included lesion diameters, patient demographics, and histologic and/or radiologic follow-up.The best way to diagnose histology was either by lumpectomy, mastectomy, or core needle biopsy (CNB).The lesion sampled by FNAB has to be the same as the CNB.Results-Of the 90 female breast FNACs in total, the majority (56%) were aged 21 to 40.A palpable breast lump was the most common presenting symptom (66.7%), and in 61.1% of cases, the Upper Outer Quadrant (UOQ) was affected.Of the ninety instances, sixty-five (72.2%) were benign, fifteen (16.7%) were malignant, and ten (11.1%) were not well enough to be diagnosed.Conclusion-The IAC Yokohama system offers exceptional accuracy for breast FNA, with high specificity and sensitivity for all tumors, all situations, and every examined BIRADS category.